Ceramide kinase: a potential anti-inflammatory target?
Ceramide 1-phosphate (C1P) possesses emerging and diversified roles in the regulation of various physiological and pathological processes, including cell proliferation, apoptosis and inflammation. Data have established a proinflammatory role for C1P and have also produced information on the structure, function, substrate specificity and regulatory mechanisms of its synthesizing enzyme, ceramide kinase (CERK). This review focuses on the rationale for designing specific inhibitors of CERK and provides evidence for the potential of CERK inhibition as a promising anti-inflammatory therapy.
Saxena
Shweta
S
Ranbaxy Research Laboratories, Department of Pharmacology, New Drug Discovery Research, Plot No 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122015, Haryana, India. shweta.saxena@ranbaxy.com
Banerjee
Manish
M
Shirumalla
Raj K
RK
Ray
Abhijit
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology*; D002518:Ceramides / Q000378:metabolism; D016503:Drug Delivery Systems; D015195:Drug Design; D007249:Inflammation / Q000201:enzymology; D010766:Phosphorylation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D002518:Ceramides; C065576:ceramide 1-phosphate; D017853:Phosphotransferases (Alcohol Group Acceptor); C066324:ceramide kinase